Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEX168 Monotherapy in Type 2 Diabetes
NCT02477865Phase 3Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2014
- Primary completion
- May 2016
- Modality
- Peptides
01
Overview
A Phase 3 trial of loxenatide in type 2 diabetes mellitus (T2DM), sponsored by Hansoh Pharmaceutical Group. Status: unknown.
02
Drugs
loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02477865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477865.